Targeting UDG is relevant to controlling the BER pathway in coordination with the APE1 endonuclease and is crucial in immunology and cancer immunotherapy (Mol et al., 2000; Parikh et al., 2000a; Slupphaug et al., 1996). The gene discussed is APEX1; the disease is cancer.